These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29998882)

  • 21. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study.
    Han M; Jiang J; Hou J; Tan D; Sun Y; Zhao M; Ning Q
    Antivir Ther; 2016; 21(4):337-44. PubMed ID: 26734984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
    Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
    [No Abstract]   [Full Text] [Related]  

  • 24. Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.
    Feld JJ; Terrault NA; Lin HS; Belle SH; Chung RT; Tsai N; Khalili M; Perrillo R; Cooper SL; Ghany MG; Janssen HLA; Lok AS;
    Hepatology; 2019 Jun; 69(6):2338-2348. PubMed ID: 30549279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial.
    Zhou Y; Yan R; Ru GQ; Yu LL; Yao J; Wang H
    Hepatol Int; 2019 Jul; 13(4):422-430. PubMed ID: 31172416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.
    Zhang K; Cao H; Liang J; Shu X; Sun H; Li G; Xu Q
    Medicine (Baltimore); 2016 Aug; 95(31):e4471. PubMed ID: 27495085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients.
    Yu XQ; Wang MJ; Yu DM; Chen PZ; Zhu MY; Huang W; Han Y; Gong QM; Zhang XX
    J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32554476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of Peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads].
    Zeng W; Yuan J; Liu YX; Zhang Y; Li SX; Yao SM; Lin YM; Chen CT; Zhao MF; Liu J; Liu Y; Zhou BP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):115-8. PubMed ID: 24044216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
    Lee JH; Lee YB; Cho EJ; Yu SJ; Yoon JH; Kim YJ
    Clin Infect Dis; 2021 Nov; 73(9):e3308-e3316. PubMed ID: 32556157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients.
    Brouwer WP; Sonneveld MJ; Xie Q; Guo S; Zhang N; Zeuzem S; Tabak F; Zhang Q; Simon K; Akarca US; Streinu-Cercel A; Hansen BE; Janssen HL
    J Viral Hepat; 2016 Jun; 23(6):419-26. PubMed ID: 26403919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
    Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients.
    Deng Z; Wang C; Li Z; Li B; Liu S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 38(12):1193-207. PubMed ID: 24384957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].
    Luo XD; Chen XP; Chen XF
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):583-588. PubMed ID: 29056007
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
    Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.